Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies

Inclusion Criteria

• Histologically or genetically proven unilateral primary or metastatic active pleural malignancy
• Radiologic workup must demonstrate that the thoracic disease is confined to only one hemi-thoracic cavity and must be deemed potentially resectable by the surgical team
• The extrathoracic disease must be controlled
• Patients must have a minimum expected duration of survival of 8 weeks as determined and documented by the attending surgeon or medical oncologist
• Patients must not have any systemic illness which precludes them from being an operative candidate
• Patients must have adequate renal function defined as: creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender less than listed value: 1 to < 2 years 0.6 mg/dL for both males and females, 2 to < 6 years 0.8 mg/dL for both males and females, 6 to < 10 years 1 mg/dL for both males and females, 10 to < 13 years 1.2 mg/dL for both males and females, 13 to < 16 years 1.5 mg/dL for males and 1.4 mg/dL for females, >= 16 years 1.7 for males and 1.4 for females
• White blood cells (WBC) is >= 1500/ul
• Absolute neutrophil count (ANC) is >= 1,000
• Platelets are >= 50,000/mm^3
• Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
• Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L
• Serum albumin >= 2 g/dL
• Patients must be recovered from any toxicity from all prior chemotherapy, immunotherapy, or radiotherapy and be at least 14 days past the date of their last treatment

Exclusion Criteria

• Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
• Patients who have failed previous hemi-thoracic platinum therapy will be ineligible (“failed” is having disease recurrence =< 3 months)
• No pregnant or lactating females
• Patients will be ineligible if they have a lymphoma diagnosis